Merck (NYSE:MRK) - Aandelenkoers, Nieuws & Analyse

MRK Overzicht aandelen

Merck & Co., Inc. is wereldwijd actief in de gezondheidszorg. Meer informatie

MRK fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	3/6
Prestaties in het verleden	5/6
Financiële gezondheid	4/6
Dividenden	5/6

Beloningen

Verhandeld tegen 65.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 15.58% per jaar groeien

De winst groeide het afgelopen jaar met 163.6%

Betaalt een betrouwbaar dividend van 3.16%

Analisten zijn het erover eens dat de aandelenkoers met 34.5% zal stijgen

Risicoanalyse

Grote eenmalige posten die de financiële resultaten beïnvloeden

Heeft een hoog schuldenniveau

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Advancing New Therapies And Expanding Global Markets Pave The Way For Long-Term Growth And Innovation

Key Takeaways Expanding product pipeline and R&D investments aim to boost revenue, long-term growth, and market share in key therapeutic areas. Ongoing demand for KEYTRUDA and strategic vaccine expansion anticipate robust revenue growth and improved market presence globally.

View narrative

US$131.08

25.7% undervalued

5.59%

Revenue growth p.a.

Updated

Merck & Co., Inc. Concurrenten

Johnson & Johnson

NYSE:JNJ

US$368.4b

Pfizer

NYSE:PFE

US$142.2b

Eli Lilly

NYSE:LLY

US$657.1b

Zoetis

NYSE:ZTS

US$79.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Merck
Historische aandelenkoersen
Huidige aandelenkoers	US$97.44
52 Week Hoogtepunt	US$134.63
52 Week Laag	US$94.48
Bèta	0.41
11 maand verandering	-8.37%
3 maanden verandering	-16.40%
1 Jaar Verandering	-4.17%
33 jaar verandering	18.42%
5 jaar verandering	11.22%
Verandering sinds IPO	8,561.33%

Recent nieuws en updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Recent updates

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Nov 15

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Nov 14

Merck: An Undervalued Dividend Machine

Nov 07

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Oct 25

Rendement voor aandeelhouders

	MRK	US Pharmaceuticals	US Markt
7D	-1.1%	-3.8%	-1.0%
1Y	-4.2%	9.8%	30.3%

Rendement versus industrie: MRK presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.8 % opleverde.

Rendement versus markt: MRK presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.3 % opleverde.

Prijsvolatiliteit

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	2.4%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: MRK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van MRK is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1891	71,000	Rob Davis	www.merck.com

Merck & Co., Inc. is wereldwijd actief in de gezondheidszorg. Het is actief via twee segmenten, Farmaceutica en Diergezondheid. Het segment Farmaceutische Producten biedt farmaceutische producten aan op het gebied van oncologie, acute zorg in ziekenhuizen, immunologie, neurowetenschappen, virologie, hart- en vaatziekten en diabetes onder de merknamen Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi en Januvia, evenals vaccinproducten bestaande uit preventieve vaccins voor kinderen, adolescenten en volwassenen onder de namen Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23 en Vaqta.

Merck & Co., Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Merck zich tot de beurswaarde?
MRK fundamentele statistieken
Marktkapitalisatie	US$244.21b
Inkomsten(TTM)	US$12.15b
Inkomsten(TTM)	US$63.17b

20.3x

Koers/Winstverhouding

3.9x

P/S-verhouding

Is MRK overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MRK resultatenrekening (TTM)
Inkomsten	US$63.17b
Kosten van inkomsten	US$14.79b
Brutowinst	US$48.39b
Overige uitgaven	US$36.24b
Inkomsten	US$12.15b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Feb 04, 2025

Winst per aandeel (EPS)	4.80
Brutomarge	76.59%
Nettowinstmarge	19.23%
Schuld/Eigen Vermogen Verhouding	85.6%

Hoe presteerde MRK op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.2%

Huidig dividendrendement

63%

Uitbetalingsratio

MRK Overzicht aandelen

Beloningen

Risicoanalyse

Advancing New Therapies And Expanding Global Markets Pave The Way For Long-Term Growth And Innovation

Merck & Co., Inc. Concurrenten

NYSE:JNJ

US$368.4b

NYSE:PFE

US$142.2b

NYSE:LLY

US$657.1b

NYSE:ZTS

US$79.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Recent updates

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab with Berahyaluronidase Alfa Met Primary Endpoints

The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business

Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Non-Epithelioid Malignant Pleural Mesothelioma

Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks

Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial

Merck Announces Canada's Drug Agency Recommends WINREVAIR (sotatercept) for Reimbursement

Merck: An Undervalued Dividend Machine

Third quarter 2024 earnings: EPS misses analyst expectations

Merck and Moderna, Inc. Initiates Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients with Certain Types of Non-Small Cell Lung Cancer (NSCLC)

CDC's ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat

Merck's KEYTRUDA® (Pembrolizumab) Receives 30th Approval from European Commission with Two New Indications in Gynecologic Cancers

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Merck Announces the Presentation of Positive Results from the Phase 2B/3 Clinical Trial (Mk-1654-004) Evaluating Clesrovimab

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease

Market Still Lacking Some Conviction On Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. to Report Q3, 2024 Results on Oct 31, 2024

Merck Is At Support And Should Go Higher (Technical Analysis)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Merck & Co., Inc. Samenvatting

20.3x

3.9x

Inkomsten en omzet

Dividenden

3.2%

63%